CCM
PCRX icon

Cobalt Capital Management’s Pacira BioSciences PCRX Stock Holding History

Cobalt Capital Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-90,000
Closed -$3.04M – 32
2023
Q4 		$3.04M Buy
+90,000
New +$2.63M 1.06% 15

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Cobalt Capital Management's PCRX Position: Q1 2024 in Review

Cobalt Capital Management sold out of Pacira BioSciences (PCRX) in Q1 2024, closing a stake of 90,000 shares — an estimated $3.04M sold.

Cobalt Capital Management first reported a position in PCRX in Q4 2023 and held it in 1 quarter. The position peaked at $3.04M in Q4 2023. 270 funds tracked by Wall St. Rank hold PCRX as of Q1 2024.

  • Cobalt Capital Management reported no remaining Pacira BioSciences position as of Q1 2024 after selling out during the quarter.
  • Cobalt Capital Management sold 90,000 Pacira BioSciences shares in Q1 2024, an estimated $3.04M.
  • Cobalt Capital Management first reported a position in Pacira BioSciences in Q4 2023 and held it in 1 quarter.
  • Cobalt Capital Management's Pacira BioSciences position peaked at $3.04M in Q4 2023.
  • 270 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2024.

Based on Cobalt Capital Management's 13F filing for Q1 2024, filed 15 May 2024.